You are here

  • Home
  • Archive
  • Volume 76, Issue 2
  • Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

Article info

Article menu

Download PDFPDF

Clinical and epidemiological research
Extended report
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

Authors

  1. Correspondence to Professor Won Park, IN-HA University, School of Medicine, Medicine/Rheumatology, 366, Seohae-Daero, Jung-Gu, Incheon 22332, Republic of Korea; parkwon{at}inha.ac.kr and Professor Dae Hyun Yoo, Division of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 222-1 Wangsimni-Ro, Seongdong-Gu, Seoul 04763, Republic of Korea; dhyoo{at}hanyang.ac.kr
View Full Text

Citation

Yoo DH, Prodanovic N, Jaworski J, et al
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Annals of the Rheumatic Diseases 2017;76:355-363.

Publication history

  • Received October 17, 2015
  • Revised April 7, 2016
  • Accepted April 9, 2016
  • First published April 29, 2016.
Online issue publication 
November 02, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/